Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients — initial experience
Niwas et al.,
Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients — initial experience,
Advances in Respiratory Medicine, doi:10.5603/ARM.a2020.0139
Retrospective 12 hospitalized patients in India treated with CQ and 17 controls, showing faster recovery with treatment. There was no significant difference in viral clearance. The CQ group mean age was 41.3 vs. 47.6 for controls.
This study is excluded in the after exclusion results of meta
analysis:
excessive unadjusted differences between groups.
recovery time, 29.2% lower, relative time 0.71, p = 0.008, treatment mean 6.3 (±2.7) n=12, control mean 8.9 (±2.2) n=17.
|
risk of no viral clearance, 183.3% higher, RR 2.83, p = 0.55, treatment 2 of 12 (16.7%), control 1 of 17 (5.9%).
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Niwas et al., 1 Nov 2020, retrospective, India, peer-reviewed, mean age 45.5, 17 authors.
Contact:
rniwasaiims@gmail.com.
Abstract: ORIGINAL RESEARCHES
Ram Niwas 1, Aneesa Shahul S 1, M K Garg 2, Vijaya Lakshmi Nag 3, Pradeep Kumar Bhatia 4,
Naveen Dutt 1, Nishant Chauhan 1, Jaykaran Charan 5, Shahir Asfahan 1, Praveen Sharma 6,
Pankaj Bhardwaj 7, Mithu Banerjee 6, Pawan Garg 8, Binit Sureka 8, Gopal Krishna Bohra 2,
Maya Gopalakrishnan 2, Sanjeev Misra 9
1
Department of Pulmonary Medicine, All India Institute of Medical Sciences Jodhpur, India
Department of General Medicine, All India Institute of Medical Sciences Jodhpur, India
3
Department of Microbiology, All India Institute of Medical Sciences Jodhpur, India
4
Department of Anaesthesiology & Critical Care, All India Institute of Medical Sciences Jodhpur, India
5
Department of Pharmacology, All India Institute of Medical Sciences Jodhpur, India
6
Department of Biochemistry, All India Institute of Medical Sciences Jodhpur, India
7
Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences Jodhpur, India
8
Department of Diagnostic & Interventional Radiology, All India Institute of Medical Sciences Jodhpur, India
9
Department of Surgical Oncology, All India Institute of Medical Sciences Jodhpur, India
2
Clinical outcome, viral response and safety profile of chloroquine
in COVID-19 patients — initial experience
Abstract
Introduction: Chloroquine and its analogues are currently being investigated for the treatment and post exposure prophylaxis of
COVID-19 due to its antiviral activity and immunomodulatory activity.
Material and methods: Confirmed symptomatic cases of COVID-19 were included in the study. Patients were supposed to receive chloroquine (CQ) 500 mg twice daily for 7 days. Due to a change in institutional protocol, initial patients received chloroquine
and subsequent patients who did not receive chloroquine served as negative controls. Clinical effectiveness was determined in
terms of timing of symptom resolution and conversion rate of reverse transcriptase polymerase chain reaction (RT-PCR) on day
14 and day 15 of admission.
Results: Twelve COVID-19 patients formed the treatment arm and 17 patients were included in the control arm. The duration
of symptoms among the CQ treated group (6.3 ± 2.7 days) was significantly (p-value = 0.009) lower than that of the control
group (8.9 ± 2.2 days). There was no significant difference in the rate of RT-PCR negativity in both groups. 2 patients out of
12 developed diarrhea in the CQ therapy arm.
Conclusion: The duration of symptoms among the treated group (with chloroquine) was significantly lower than that of the control
group. RT-PCR conversion was not significantly different between the 2 groups.
Key words: COVID-19, chloroquine, viral conversion, safety profile
Adv Respir Med. 2020; 88: 515–519
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit